Area of research
Virology · Infectious Diseases
Research interest
Research interests include HIV Research and Treatment, Immune Cell Function and Interaction, HIV/AIDS drug development and treatment, and Viral Infections and Outbreaks Research.
microRNA-422a promotes HIV replication and innate immune evasion by targeting MECP2
Myeloid-mesenchymal crosstalk drives ARG1-dependent profibrotic metabolism via ornithine in lung fibrosis
A viral assembly inhibitor blocks SARS-CoV-2 replication in airway epithelial cells.
High-resolution Inference of Multiplexed Anti-HIV Gene Editing using Single-Cell Targeted DNA Sequencing
Systematic benchmarking of single-cell ATAC-sequencing protocols
Systematic benchmarking of single-cell ATAC-sequencing protocols
Human galectin-9 potently enhances SARS-CoV-2 replication and inflammation in airway epithelial cells
Human galectin-9 potently enhances SARS-CoV-2 replication and inflammation in airway epithelial cells.
The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency.
Elevated Galectin-9 across the human brain correlates with HIV neuropathology and detrimental cognitive states.
Host variation in type I interferon signaling genes (MX1), C-C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers predict viral reservoir size.
IL10 trains macrophage profibrotic function after lung injury.
Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19.
Galectin-9 protects humanized-ACE2 immunocompetent mice from SARS-CoV-2 infection.
The Hypoxia-regulated Ectonucleotidase CD73 is a Host Determinant of HIV Latency
TCF-1 regulates HIV-specific CD8+ T cell expansion capacity
Efficient generation of isogenic primary human myeloid cells using CRISPR-Cas9 ribonucleoproteins
Efficient generation of isogenic primary human myeloid cells using CRISPR-Cas9 ribonucleoproteins.
Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity <i>Ex Vivo and In Vivo</i>.
Hyaluronic acid is a negative regulator of mucosal fibroblast-mediated enhancement of HIV infection.
Host variation in type I interferon signaling genes ( <i>MX1</i> ), <i>CCR5</i> Δ <i>32</i> , and MHC class I alleles in treated HIV+ non-controllers predict viral reservoir size
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.
TCF-1 regulates HIV-specific CD8+ T cell expansion capacity
FOXO1 promotes HIV latency by suppressing ER stress in T cells.
FOXO1 promotes HIV Latency by suppressing ER stress in T cells
μ-Lat: A mouse model to evaluate human immunodeficiency virus eradication strategies.
Efficient Generation of Isogenic Primary Human Myeloid Cells using CRISPR-Cas9 Ribonucleoproteins
TCF-1 regulates the stem-like memory potential of HIV-specific CD8+ T cells in elite controllers
Durable Control of HIV-1 Using a Staphylococcus aureus Cas9-Expressing Lentivirus Co-Targeting Viral Latency and Host Susceptibility